Cellectis(ENXT) ALCLS

Cellectis S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in immuno-oncology. Founded in 1999, the company focuses on developing gene-edited T-cell therapies to target and destroy cancer cells.

Products and Services

• Allogeneic CAR T-cell product candidates for various cancers
• Strategic partnerships with leading biotech firms and research institutions
• Innovative gene-editing technologies for therapeutic applications

Growth Outlook

• Strong pipeline with multiple CAR T-cell candidates in clinical trials
• Recent partnerships enhance research capabilities and market reach
• Increasing demand for advanced cancer therapies supports growth potential

Financial Highlights

• Q2 2026 revenue of 5.23 million, showing resilience in challenging market conditions
• Trailing twelve months (TTM) gross profit margin at 74.68%, indicating strong product demand
• Cash and short-term investments of 166.85 million, providing operational flexibility

Cellectis S.A. operates in a dynamic sector with a focus on innovative cancer therapies. The company's robust pipeline and strategic collaborations position it well for future growth. Recent financial performance reflects resilience, with a notable gross profit margin indicating strong demand for its products. The substantial cash reserves provide a buffer for ongoing research and development efforts, allowing the company to navigate the complexities of the biotechnology landscape effectively. As the demand for advanced cancer treatments continues to rise, Cellectis S.A. stands out as a key player in the immuno-oncology field.